Cargando…

The present and future of PI3K inhibitors for cancer therapy

Phosphoinositide-3- kinase (PI3K) signaling regulates cellular proliferation, survival and metabolism, and its aberrant activation is one of the most frequent oncogenic events across human cancers. In the last few decades, research focused on the development of PI3K inhibitors, from preclinical tool...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castel, Pau, Toska, Eneda, Engelman, Jeffrey A., Scaltriti, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809509/ https://www.ncbi.nlm.nih.gov/pubmed/35118422 http://dx.doi.org/10.1038/s43018-021-00218-4

Ejemplares similares

Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer
por: Castel, Pau, et al.
Publicado: (2019)

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
por: Castel, Pau, et al.
Publicado: (2016)

Overview of the relevance of PI3K pathway in HR-positive breast cancer
por: Vasan, N, et al.
Publicado: (2019)

The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation
por: Ladewig, Erik, et al.
Publicado: (2022)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
por: Arruabarrena-Aristorena, Amaia, et al.
Publicado: (2022)

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor
por: Juric, Dejan, et al.
Publicado: (2014)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth
por: Wolfe, Andrew L., et al.
Publicado: (2021)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs
por: Osmanbeyoglu, Hatice U., et al.
Publicado: (2017)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth
por: Bago, Ruzica, et al.
Publicado: (2016)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Challenges in the clinical development of PI3K inhibitors
por: Massacesi, Cristian, et al.
Publicado: (2013)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

WT1 Interacts with MAD2 and Regulates Mitotic Checkpoint Function
por: Shandilya, Jayasha, et al.
Publicado: (2014)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

Prohibitin is required for transcriptional repression by the WT1-BASP1 complex
por: Toska, Eneda, et al.
Publicado: (2013)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
por: Garrett, Joan T., et al.
Publicado: (2011)

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
por: Wu, Yi-Hui, et al.
Publicado: (2020)

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
por: Mizrachi, Aviram, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kv4dtrq9ga0r8jgaf4gfrqitq3